This page has beta status

BMBS COST Action B25
Physiologically based Pharmaco-Toxicokinetics and Dynamics

The main objective of the COST Action B25 is to improve the utility and interpretation of

scientific information obtained either during product development or, subsequently, through

observations in humans, to predict the safe and effective use of drugs and other chemicals.

Exposure to drugs and other chemicals is expressed in terms of the mass of compound.

However, it is the concentration of the compound that determines the magnitude of interaction

with the molecular targets responsible for the desirable and for the undesirable effects of these

chemicals. Physiologically based approaches provide a mechanistically-based means of

relating external exposure to internal, or active site, concentration and effect, permitting

extrapolation throughout a wide range of circumstances, whilst providing insight into the

fundamental processes involved.

Physiologically based approaches are potentially very powerful, and can assist in product

development, by improving compound selection, in the design and interpretation of premarketing

studies, in dose selection in different patient groups, in assessing the extent and

causes of interindividual variation in response and in the risk assessment of drugs and other

chemicals, including quantitative extrapolation from experimental animals to man. Such

approaches also provide unparalleled opportunities for the application of in vitro and

computer-based techniques, to acquire the appropriate parameters, and thereby reduce or

replace animal experimentation.

Hence, the COST Action B25 will provide a highly effective means of improving interaction

between scientists from Academia, Industry and Governmental sectors.

The working framework of the Action is based on the experience gained during previous

Actions, COST B1 and COST B15. Both COST Actions were very effective in facilitating the

exchange of information between the various interested parties in the fields of drug

development and drug and chemical safety. This ranged from in vitro studies of kinetic and

dynamic processes, biomarkers of clinical effect, to models of disease progression and the

simulation of clinical trials. Both COST Actions were also effective in stimulating European

research in the respective areas. Whilst COST Action B15 was concerned with modelling,

physiologically based approaches were not addressed. Nevertheless, during the COST Action

B15 it became apparent that such approaches have considerable potential and that they would

benefit considerably from a dedicated COST Action. Hence, the COST Action B25 is built

upon, but distinct from, these previous COST Actions.

(Descriptions are provided by the Actions directly via e-COST.)

General Information*

Chair of the Action:

Prof Alan BOOBIS (UK)

Vice Chair of the Action:


Science officer of the Action:


Administrative officer of the Action:

Ms Jeannette NCHUNG ORU


Action Fact Sheet

Download AFS as .RTF

Memorandum of Understanding

Download MoU as PDF

Progress Report

Download Progress Report as PDF

Final Report

Download Final Report as PDF


Action website:

* content provided by e-COST.
Data is synchronised once per night.


Last updated: 02 May 2011 top of page